Interferons have been shown to be able to regulate PD-L1 expression not only on tumor (25) but as well on several non-tumor cell types: IFNγ increases PD-L1 in dermal fibroblasts (15), hepatic stellate cells (27) and DC (28, 29); the up-regulation of PD-L1 in DC by IFNβ contributes to immunomodulatory effects of this cytokine in multiple sclerosis and in lipopolysaccharide-induced immune paralysis (30, 31) and the expression of PD-L1 in hepatocytes and in myeloid cells in vitro can be augmented by IFNα (29, 32). The gene discussed is IFNA1; the disease is neoplasm.